Short answer
MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO Kent Hawryluk departs July 13, 2026 without reported dispute, creating leadership transition risk.
MBX Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Kent Hawryluk departs July 13, 2026 without reported dispute, creating leadership transition risk
- Steven Hoerter becomes CEO from executive chairman role at $665,000 base salary and 60% target bonus
- Hoerter receives options on 331,000 shares and RSUs covering 71,000 shares, increasing potential dilution
- CFO John Smither appointed permanently at $530,000 salary and 40% target bonus after interim service
- Smither receives $150,000 relocation bonus, options on 130,000 shares, and RSUs covering 28,000 shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MBX Biosciences, Inc. 8-K filings
Get the next MBX 8-K as it lands
Follow MBX for push alerts, or ask the research agent what this filing means.